ASSOCIATION BETWEEN METABOLIC SYNDROME RATE AND CONCURRENT PSYCHIATRIC DIAGNOSIS IN PATIENTS WITH BIPOLAR DISORDER

Yıl 2022, Cilt: 8 Sayı: 3, 29 - 39, 31.12.2022

Deniz Yıldız

Öz

Objective: Bipolar disorder (BPD) patients were determined to have shorter survival than the general population due to reasons such as early cardiovascular diseases and obesity and this causes a decrease in quality of life and an increase in healthcare costs. Considering this, we aimed to determine the MS rate and the presence of concurrent psychiatric diagnosis in BPD patients who admitted to the outpatient clinic of the Psychiatry Department of Canakkale Onsekiz Mart University Medical Faculty. Materials and Methods: Eighty euthymic patients with BPD diagnosis were included in the study. Patients were evaluated with Hamilton Depression Rating Scale, Young Mania Rating Scale and SCID I and II. The diagnosis of MS was made according to ATP III criteria. Results: While 22.2% of the patients (n=6) of 18-35 years of age had MS, MS was present in 45% of the patients (n=21) of 35 years or older. The rate of MS was significantly higher in the patients under 35 years of age compared to the patients 35 years or older (p<0.05). The SCID-I evaluation revealed that 20 of the 80 patients (25%) with the diagnosis of BPD had concurrent psychiatric diagnosis. BPD patients with concurrent psychiatric diagnosis had a higher rate of MS compared to the whole study group, while the difference was not statistically significant. Conclusion: The rate of MS was higher in BPD patients compared to the general population. BPD patients with concurrent psychiatric diagnosis had a higher rate of MS compared to the whole study group, while the difference was not statistically significant. Our results show the importance of implementing a multidisciplinary approach and investigation of MS components in BPD.

Anahtar Kelimeler

BIPOLAR DISORDER, PSYCHIATRIC DIAGNOSIS, METABOLIC SYNDROME

Kaynakça

• 1. Revicki DA, Matza LS, Flood E, Lloyd A. Bipolar disorder and health-related quality of life : review of burden of disease and clinical trials. Pharmacoeconomics. 2005;23(6):583–594. doi: 10.2165/00019053-200523060-00005.  2. Miller C, Bauer MS. Excess mortality in bipolar disorders. Curr Psychiatry Rep. 2014;16(11):499. doi: 10.1007/s11920-014-0499-z.
•  3. Taylor, V., Mac Queen, G. (2006). Associations Between Bipolar Disorder And Metabolic Syndrome: A Review. J Clin Psychiatry. 67:1034-1041.
• 4. Toalson, P., Ahmed, S., Hardy, T., Kabınoff, G.(2006). The Metabolic Syndrome In Patients With Severe Mental Illnesses. Prim Care Companion J Clin Psychiatry. 6:152-158.
• 5. Malhotra, S., Mcelroy, S. L. (2003). Associations Between Metabolic Syndrome And Psychiatric Disorder. Prim Psychiatry. 10:37-44.
• 6. Yumru, M., Savas, H. A., Kurt E. (2007). Atypical Antipsychotics Related Metabolic Syndrome İn Bipolar Patients. J Affect Disord. 98:247-252.
• 7. Zımmet, P., Maglıano, D., Matsuzawa, Y., Albertı, G., Shaw, J.(2005) The Metabolic Syndrome: A Global Public Health Problem And A New Definition. J Atheroscler Thromb. 12(6):295-300.
• 8.Ferrari AJ, Stockings E, Khoo JP, Erskine HE, Degenhardt L, Vos T, Whiteford HA. The prevalence and burden of bipolar disorder: findings from the global burden of disease study 2013. Bipolar Disord. 2016;18(5):440–450. doi: 10.1111/bdi.12423 9. Mcıntyre, R. S., Danılewıtz, M., Lıauw, S. S., Kemp, D. E., Nguyen, H. T., Kahn, L. S., Kucyı, A., Soczynska, J. K., Woldeyohannes, H. O., Lachowskı, A., Kım, B., Nathanson, J., Alsuwaıdan, M., Taylor, V. H.(2010). Bipolar Disorder And Metabolic Syndrome: An İnternational Perspective. J Affect Disord, Nov. 126(3):366-87.
• 10. Roshanaeı-Moghaddam, B.(2009). Premature Mortality From General Medical İllnesses Among Persons With Bipolar Disorder: A Review. Katon W.Psychiatr Serv, Feb. 60 (2):147-56
• 11. Grundy, S. M., Brewer, H. B. JR, Cleeman, J. I., Smıth, S. C. JR, Lenfant, C. (2004). American Heart Association; National Heart, Lung, And Blood Institute. Definition Of Metabolic Syndrome: Report Of The National Heart, Lung, And Blood Institute/American Heart Association Conference On Scientific İssues Related To Definition. Circulation. 109(3):433-8.
• 12. National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143-3421
• 13. Jakovljevıc, M., Zeljka, C., Ljubıcıc, D.. (2007). Mental Disorders And Metabolic Syndrome: A Fatamorgana Or Warning Reality? Psychiatr Danub. 19:76-86.
• 14. Cheskın, L. J., Bartlett, S. J., Zayas, R. (1999). Prescription Medications: A Modifiable Contributor To Obesity. South Med J. 92:898-904.
• 15. Maına, G., Salvı, V., Vıtaluccı, A. (2008). Prevalence And Correlates Of Overweight İn Drug-Naive Patients With Bipolar Disorder. J Affect Disord. 110:149-155.
• 16. Fagıolını, A., Chengappa, K. N. R., Soreca, I.. (2008). Bipolar Disorder And The Metabolic Syndrome: Causal Factors, Psychiatric Outcomes And Economic Burden. Cns Drugs. 22:655-669.
• 17. Türkiye Endokrinoloji Ve Metabolizma Derneği Metabolik Sendrom Kılavuzu. Http://Www.Turkendokrin.Org/Grup/Metabolik_Sendrom.Pdf , Erişim Tarihi :31/03/2019
• 18. Fagıolını, A., Frank, E., Scott, J. A. (2005). Metabolic Syndrome İn Bipolar Disorder: Findings From The Bipolar Disorder Center For Pennsylvanians. Bipolar Disord. 7:424-430.
• 19. Fıedorowıcz, J.G., Palagummı, N.M., Forman-Hoffman, V.L., Mıller, D.D., Haynes, W.G. (2008).Elevated Prevalence Of Obesity, Metabolic Syndrome, And Cardiovascular Risk Factors İn Bipolar Disorder.Ann Clin Psychiatry. Jul-Sep;20(3):131-7.
• 20. Correll, C. U., Frederıckson, A. M., Kane, J. M. (2008). Equally İncreased Risk For Metabolic Syndrome İn Patients With Bipolar Disorder And Schizophrenia Treated With Second-Generation Schizophrenia Treated With Second-Generation. Bipolar Disord. 10:788-797
• 21. Krıshnan, K. R. (2005). Psychiatric And Medical Comorbidities Of Bipolar Disorder. Psychosomatic Medicine: 67 (1):1-8.
• 22. Mcelroy, S. L., Altshuler, L. L., Suppes, T., Keck, P. E., Frye, M. A., Denıcoff, K. D., Nolen, W. A., Kupka, R. W., Leverıch, G. S., Rochussen, J. R., Rush, A. R., Post, R. M.(2001). Axis I Psychiatric Comorbidity And Its Relationship To Historical Illness Variables İn 288 Patients With Bipolar Disorder, Am J Psychiatry. 158:420-426.
• 23. Geoffroy, P. A., Etaın, B., Scott, J., Henry, C., Jamaın, S., Leboyer, M., Bellıvıer, F. (2013). Reconsideration Of Bipolar Disorder As A Developmental Disorder: Importance Of The Time Of Onset. J Phsy Paris. 2013 Sept 107 (4):278-285.
• 24. Perlıs, R. H., Mıyahara, S., Marangell, L. B., Wısnıewskı, S. R., Ostacher, M., Delbello, M. P., Bowden, C. L., Sachs, G. S., Nıerenberg, A. A.; Step-Bd Investigators. (2004). Long-Term İmplications Of Early Onset İn Bipolar Disorder: Data From The First 1000 Participants İn The Systematic Treatment Enhancement Program For Bipolar Disorder (Step-Bd). Biol Psychiatry. 2004 May 1. 55(9):875-81.
• 25. Sımon, N. M., Otto, M. W., Wısnıewskı, S. R., Fossey, M., Sagduyu, K., Frank, E., Sachs, G. S., Nıerenberg, A. A., Thase, M. E., Pollack, M. H. (2004). Anxiety Disorder Comorbidity İn Bipolar Disorder Patients: Data From The First 500 Participants İn The Systematic Treatment Enhancement Program For Bipolar Disorder (Step-Bd).Am J Psychiatry, 2004 Dec. 161(12):2222-9.
• 26. Doğan, O., Gülmez, H., Ketenoğlu, C., Kılıçkap, Z.Ö. (1995). Ruhsal Bozuklukların Epidemiyolojisi, 1. Baskı, Sivas. Dilek Matbaası, S. 50-52.
• 27. Oyeçkin DG. Bir Grup Şizofreni Ve Şizoaffektif Bozukluk Hastasında Metabolik Sendrom Sıklığı. Anadolu Psikiyatr Derg. 2009; 10:26-33